Alnylam Pharmaceuticals Inc

Business Description

Alnylam Pharmaceuticals is a Cambridge, Massachusetts-based biotech company founded in 2002 that researches and sells medicines using a technology called RNA interference, which works by silencing specific genes that cause disease. The company currently markets several approved treatments for conditions such as rare inherited diseases, high cholesterol, and hemophilia, while running a broad pipeline of experimental drugs targeting everything from heart disease and obesity to Alzheimer's, Parkinson's, and certain cancers. Alnylam works alongside major pharmaceutical partners including Novartis, Roche, Sanofi, and Regeneron to advance and distribute its therapies across the United States and global markets.